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The use of antibodies to block pathways inhibiting the endog-
enous immune response to cancer, known as checkpoint
blockade therapy, has stirred up a great deal of excitement
among scientists, physicians, and patients alike. Clinical
trials evaluating the safety and efficacy of antibodies that
block the T cell inhibitory molecules CTLA-4 and PD-1 have
reported success in treating subsets of patients with
metastatic melanoma and renal cell carcinoma. Antibodies
targeting these pathways have been approved for clinical
use, and patients once unresponsive to any sort of con-
ventional treatment have shown good and stable clinical
responses—some remaining free of disease progression for
many years. What types of cancer can benefit of immuno-
therapy and the factors that determine whether a patient
will respond to treatment are now pressing questions. In
the past month, seven new studies have begun to point
toward the answers.Checkpoint blockade therapy targets inhibitory pathways that keep T cells
(shown in blue) from responding to tumor cells (represented in yellow). Upon
release of such inhibition, the endogenous immune response can limit can-
cer growth (image from iStockphoto).The first three reports expand the list of cancers that can be
treated with checkpoint blockade therapy. Herbst et al. find
that treatment with MPDL3280A, a monoclonal antibody
specific for the PD-1 ligand (PD-L1), promotes therapeutic
responses in patients with advanced non-small-cell lung
cancer, renal cell cancer, and melanoma (Herbst et al.
2014), while Powles et al. show that the same antibody can
be used to treat urothelial bladder cancer (Powles et al.
2014). Both groups report durable responses and low
toxicity of the treatment, which is particularly important
as high-grade adverse effects have limited the use of
immunotherapy for cancer until now. In addition, Robert
et al. provide evidence that patients with metastatic mela-
noma without the BRAF mutation present better responsesto immunotherapy with Nivolumab, a monoclonal antibody
that blocks PD-1, than to conventional chemotherapy
(Robert et al. 2014).
Thus, the list of cancers that can be targeted with immuno-
therapy is growing. However, only a fraction of patients
treated will respond. What parameters predict a good
response? Identifying biomarkers has been a long-sought
goal in immunotherapy. The expression of PD-L1 in cancer
cells is an obvious candidate, as it can directly turn off the
immune response by inhibiting the activity of cytotoxic
T cells infiltrating the tumor, but PD-L1 expression in tumor
cells has had little predictive power. Analyzing samples
from patients with melanoma treated with another PD-1-
specific antibody, Pembrolizumab, Tumeh et al. establish a
set of conditions that correlates with good response to
therapy (Tumeh et al. 2014). These include the presence of
cytotoxic T cells in the tumor, the expression of PD-L1 and
PD-1 in immune cells in the tumor margin, and less
complexity (in terms of antigen receptors) in the T cell
population in the tumor. In support of these findings, Robert
et al. and Herbst et al. also observe that PD-L1 expression
in immune cells is a good biomarker of response to
immunotherapy.
The finding that complexity of the T cell population in the tu-
mor infiltrate can predict good response to checkpoint
blockade therapy highlights the importance of understanding
which antigens in the tumor can elicit an effective antitumor
immune response. Previous studies suggested that tumors
with a high load of somatic mutations are more likely to
respond to immunotherapy, as in theory these tumors would
have a higher diversity of neoantigens that can trigger an im-
mune response when the CTLA-4/PD-1 inhibition is by-
passed. To test this hypothesis, Snyder et al. carry out
whole-exome sequencing of tumors frommelanoma patients
under therapy with CTLA4-specific antibodies Ipilimumab
and Pembrolizumab (Snyder et al. 2014). While the data
indeed show that high load of mutations correlate with
responsiveness to therapy in many cases, surprisingly
some tumors with a high load of somatic mutations fail to
respond to checkpoint blockade. Computational analysis
allows them to identify neoepitopes, antigens created by so-
matic mutations eliciting a T cell response, that are shared by
the patients that respond to immunotherapy. It is thus
possible that the nature of themutations present in the tumor,
not just the quantity, is a determining factor in responsive-
ness to therapy.
Identifying which mutations give rise to neoantigens that
are functionally important for triggering an antitumor
response has been particularly challenging. Yadav et al.
attempt to facilitate the discovery of new mutant peptides
by characterizing their general properties (Yadav et al.
2014). By carrying out whole-exome sequencing of two
mouse tumor cell lines and comparing the data with the
reference mouse exome sequences, they are able to predict
candidate neoantigens in the tumor. Only a fraction of the
neoantigens is predicted to bind toMHC (major histocompat-
ibility complex) molecules, which present antigens to T cells.Cell 160, January 15, 2015 ª2015 Elsevier Inc. 7
An even smaller fraction binds to the MHC, as determined
by mass spectrometry. The predicted mutant peptides that
are immunogenic in vivo have solvent-exposed mutations,
which are accessible to recognition by the T cell antigen re-
ceptor, as a common feature. Interestingly, these neoanti-
gens are derived from proteins that are unlikely to contribute
to tumorigenesis, confirming that passengermutations play a
significant role in shaping the immunogenicity of cancer cells.
This platform could potentially be used to identify immuno-
genic antigens in any cancer cell type.
It is not entirely clear why the number of functionally
relevant immunogenic antigens in the tumor is so low. One
possibility is that mutations that give rise to highly immuno-
genic neoantigens are selected against during tumor growth.
Indeed, Gubin et al. report that in amousemodel of sarcoma,
resistance to immune-mediated rejection arises from loss of
a major immunogenic antigen in the tumor cells (Gubin et al.
2014). The good news is that checkpoint blockade therapy
can rescue the endogenous immune response, despite the
loss of that antigen. The endogenous T cells infiltrating the
tumor, once released from the inhibitory effect of CTLA-4
and PD-1, recognize neoantigens originating from two
other mutations in the Alg8 and Lama4 genes and are thus
able to reject the tumor. Importantly, vaccination of the
tumor-bearing mice with these antigens also elicits tumor
rejection, providing evidence that cancer vaccines can be
efficacious, if the right combination of antigen and adjuvant
is determined.
It is tempting to ask whether immunotherapy is evolving
to become standard care for cancer patients, beyond
those with advanced disease. Will it prove to be more effi-
cacious than standard chemotherapy in cancers other
than BRAF-negative melanoma? Is there a place for
therapeutic regimens that combine checkpoint blockade
with other strategies? While we are nowhere near having
all the answers, these studies provide a wealth of data
supporting the idea that somatic mutations in cancer cells
are an important target of endogenous anti-tumor re-
sponses. Checkpoint blockade is effective at rescuing the
anti-tumor effect and it is plausible that understanding the
dynamics of the response to this therapy will also help
the development of alternative and personalized ap-
proaches to treat cancer.
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